Valeant Pharmaceuticals, Inc. | Bausch Health | insurance violation | 2018 | CA-INS | $1,875,000 |
Johnson & Johnson, Inc. | Johnson & Johnson | insurance violation | 2020 | NC-INS | $150,000 |
Schering-Plough Corporation | Merck | investor protection violation | 2003 | SEC | $1,000,000 |
Allergan Inc. | AbbVie | investor protection violation | 2017 | SEC | $15,000,000 |
Aegerion Pharmaceuticals | Amryt Pharma | investor protection violation | 2017 | SEC | $4,100,000 |
Cytrx Corporation | CytRx | investor protection violation | 2017 | SEC | $75,000 |
Clovis Oncology Inc. | Clovis Oncology | investor protection violation | 2018 | SEC | $20,000,000 |
Valeant Pharmaceuticals International, Inc. | Bausch Health | investor protection violation | 2017 | MULTI-AG | $145,000,000 |
Mylan N.V. | Viatris | investor protection violation | 2019 | SEC | $30,000,000 |
Amyris, Inc. | Amyris | investor protection violation | 2021 | SEC | $300,000 |
St. Jude Medical Inc. | Abbott Laboratories | kickbacks and bribery | 2011 | DOJ_CIVIL | $16,000,000 |
Kos Pharmaceuticals | AbbVie | kickbacks and bribery | 2010 | FDA | $41,500,000 |
Novartis Pharmaceuticals | Novartis | kickbacks and bribery | 2015 | USAO | $390,000,000 |
Schering-Plough Corporation | Merck | kickbacks and bribery | 2004 | DOJ_CIVIL | $345,000,000 |
Novo Nordisk A/S | Novo Holdings A/S | kickbacks and bribery | 2009 | DOJ_CRIMINAL | $9,000,000 |
AstraZeneca PLC | AstraZeneca | kickbacks and bribery | 2016 | SEC | $5,522,000 |
GlaxoSmithKline plc | GlaxoSmithKline | kickbacks and bribery | 2016 | SEC | $20,000,000 |
Salix Pharmaceuticals Inc. | Bausch Health | kickbacks and bribery | 2016 | USAO | $54,000,000 |
Biovail Pharmaceuticals Inc. | Bausch Health | kickbacks and bribery | 2009 | USAO | $24,647,876 |
Pharmacia & Upjohn Company Inc. | Pfizer | kickbacks and bribery | 2007 | USAO | $19,700,000 |
Pharmacia & Upjohn Company LLC | Pfizer | kickbacks and bribery | 2007 | USAO | $15,000,000 |
AbbVie Inc. | AbbVie | kickbacks and bribery | 2018 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $1,800,000 |
Alere Inc. | Abbott Laboratories | kickbacks and bribery | 2017 | MS-AG | $2,000,000 |
GlaxoSmithKline, LLC | GlaxoSmithKline | kickbacks and bribery | 2014 | MULTI-AG | $105,000,000 |
Kos Pharmaceuticals | AbbVie | kickbacks and bribery | 2010 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $4,454,432 |
Mallinckrodt ARD LLC | Mallinckrodt | kickbacks and bribery | 2019 | DOJ_CIVIL | $15,400,000 |
Novartis Pharmaceuticals Corporation | Novartis | kickbacks and bribery | 2015 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $83,129,754 |
Pfizer, Inc. | Pfizer | kickbacks and bribery | 2009 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $331,485,170 |
Salix Pharmaceuticals Inc. | Bausch Health | kickbacks and bribery | 2016 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $7,470,000 |
Sanofi US Services, Inc. | Sanofi | kickbacks and bribery | 2013 | MULTI-AG | $617,000 |
Schering-Plough Corporation | Merck | kickbacks and bribery | 2004 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $292,969,482 |
TAP Pharmaceutical Products, Inc. | Takeda Pharmaceutical | kickbacks and bribery | 2006 | KY-AG | $600,000 |
TAP Pharmaceutical Products, Inc. | Takeda Pharmaceutical | kickbacks and bribery | 2006 | WI-AG | $798,000 |
Teva Pharmaceuticals USA Inc. | Teva Pharmaceutical Industries | kickbacks and bribery | 2014 | IL-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $12,100,000 |
Bristol-Myers Squibb | Bristol-Myers Squibb | kickbacks and bribery | 2016 | CA-INS | $30,000,000 |
Novartis Pharmaceuticals Corporation | Novartis | kickbacks and bribery | 2020 | CA-AG | $11,800,000 |
Novartis Pharmaceuticals Corp. | Novartis | kickbacks and bribery | 2020 | MULTI-AG | $103,000,000 |
Pacira Pharmaceuticals, Inc. | Pacira BioSciences | kickbacks and bribery | 2020 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $3,500,000 |
Parexel International, LLC | Parexel International | labor relations violation | 2012 | NLRB | $253,000 |
Amgen, Inc. | Amgen | labor relations violation | 2011 | NLRB | $40,000 |
Merck and Company, Inc. | Merck | labor relations violation | 2009 | NLRB | $10,710 |
Merck & Co., Inc. | Merck | labor relations violation | 2008 | NLRB | $100,000 |
Schering-Plough | Merck | labor relations violation | 2007 | NLRB | $8,200 |
Boehringer Ingelheim Pharmaceutical, Inc. | Boehringer Ingelheim | labor relations violation | 2004 | NLRB | $50,000 |
Advanced Medical Optics | Abbott Laboratories | labor relations violation | 2004 | NLRB | $16,800 |
Therasense, Inc. | Abbott Laboratories | labor relations violation | 2003 | NLRB | $236,827 |
Actavis Kadian, LLC | AbbVie | Medicare Coverage Gap Discount Program violation | 2013 | CMS | $116,703 |
Intermune, Inc. | Roche | Medicare Coverage Gap Discount Program violation | 2013 | CMS | $5,641 |
Intermune, Inc. | Roche | Medicare Coverage Gap Discount Program violation | 2013 | CMS | $16,215 |
Amneal Pharmaceutical, LLC | Amneal Pharmaceuticals | Medicare Coverage Gap Discount Program violation | 2015 | CMS | $5,909 |
Amneal Pharmaceutical, LLC | Amneal Pharmaceuticals | Medicare Coverage Gap Discount Program violation | 2015 | CMS | $9,440 |
Amneal Pharmaceutical, LLC | Amneal Pharmaceuticals | Medicare Coverage Gap Discount Program violation | 2016 | CMS | $10,788 |
Amneal Pharmaceuticals, LLC | Amneal Pharmaceuticals | Medicare Coverage Gap Discount Program violation | 2016 | CMS | $12,367 |
Amneal Pharmaceuticals, LLC | Amneal Pharmaceuticals | Medicare Coverage Gap Discount Program violation | 2019 | CMS | $12,968 |
Wockhardt USA | Wockhardt Limited | Medicare Coverage Gap Discount Program violation | 2020 | CMS | $111,824 |
Alnylam Pharmaceuticals, Inc. | Alnylam Pharmaceuticals | Medicare Coverage Gap Discount Program violation | 2023 | CMS | $31,959 |
CAMBRIDGE MAJOR LABORATORIES INC | Alcami | motor vehicle safety violation | 2006 | FMCSA | $18,560 |
EMD CHEMICALS INCORPORATED | Merck KGaA (EMD) | motor vehicle safety violation | 2006 | FMCSA | $7,614 |
CAMBRIDGE MAJOR LABORATORIES INC | Alcami | motor vehicle safety violation | 2005 | FMCSA | $15,820 |
EMD CHEMICALS INCORPORATED | Merck KGaA (EMD) | motor vehicle safety violation | 2004 | FMCSA | $13,170 |
Cody Laboratories Inc | Lannett Co. | motor vehicle safety violation | 2018 | FMCSA | $8,510 |
Mallinckrodt, Inc. | Mallinckrodt | nuclear safety violation | 2000 | NRC | $125,000 |
Endo Health Solutions Inc. | Endo International | off-label or unapproved promotion of medical products | 2014 | FDA | $192,700,000 |
Johnson & Johnson | Johnson & Johnson | off-label or unapproved promotion of medical products | 2013 | FDA | $2,200,000,000 |
Wyeth Pharmaceuticals Inc. | Pfizer | off-label or unapproved promotion of medical products | 2013 | FDA | $490,900,000 |
Par Pharmaceutical Companies Inc. | Endo International | off-label or unapproved promotion of medical products | 2013 | FDA | $45,000,000 |
GlaxoSmithKline LLC | GlaxoSmithKline | off-label or unapproved promotion of medical products | 2012 | FDA | $3,000,000,000 |
Abbott Laboratories Inc. | AbbVie | off-label or unapproved promotion of medical products | 2012 | FDA | $1,500,000,000 |
Cypress Pharmaceutical Inc. | Currax Pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | FDA | $2,800,000 |
Merck, Sharp & Dohme | Merck | off-label or unapproved promotion of medical products | 2011 | FDA | $950,000,000 |
Pfizer Inc. | Pfizer | off-label or unapproved promotion of medical products | 2011 | FDA | $14,500,000 |
Scios Inc. | Johnson & Johnson | off-label or unapproved promotion of medical products | 2011 | FDA | $85,000,000 |
Novo Nordisk Inc. | Novo Holdings A/S | off-label or unapproved promotion of medical products | 2011 | FDA | $25,000,000 |
UCB Inc. | UCB | off-label or unapproved promotion of medical products | 2011 | FDA | $34,000,000 |
Forest Pharmaceuticals Inc. | AbbVie | off-label or unapproved promotion of medical products | 2011 | FDA | $164,000,000 |
Elan Corporation PLC | Perrigo | off-label or unapproved promotion of medical products | 2010 | FDA | $203,000,000 |
Eisai Inc. | Eisai | off-label or unapproved promotion of medical products | 2010 | FDA | $11,000,000 |
Novartis Pharmaceuticals Corporation | Novartis | off-label or unapproved promotion of medical products | 2010 | FDA | $422,500,000 |
Allergan Inc. | AbbVie | off-label or unapproved promotion of medical products | 2010 | FDA | $600,000,000 |
Ortho-McNeil Pharmaceutical LLC | Johnson & Johnson | off-label or unapproved promotion of medical products | 2010 | FDA | $81,000,000 |
AstraZeneca LP | AstraZeneca | off-label or unapproved promotion of medical products | 2010 | FDA | $520,000,000 |
Amgen Inc. | Amgen | off-label or unapproved promotion of medical products | 2012 | FDA | $762,000,000 |
Inspire Pharmaceuticals Inc. | Merck | off-label or unapproved promotion of medical products | 2015 | USAO | $5,900,000 |
Warner Chilcott PLC | AbbVie | off-label or unapproved promotion of medical products | 2015 | FDA | $125,000,000 |
Shire Pharmaceuticals LLC | Takeda Pharmaceutical | off-label or unapproved promotion of medical products | 2014 | FDA | $56,500,000 |
Boehringer Ingelheim Pharmaceuticals Inc. | Boehringer Ingelheim | off-label or unapproved promotion of medical products | 2012 | FDA | $95,000,000 |
Novartis Vaccines & Diagnostics Inc. and Novartis Pharmaceuticals Corporation | Novartis | off-label or unapproved promotion of medical products | 2010 | FDA | $72,500,000 |
Pfizer Inc. | Pfizer | off-label or unapproved promotion of medical products | 2009 | FDA | $2,300,000,000 |
Eli Lilly and Company | Eli Lilly | off-label or unapproved promotion of medical products | 2009 | FDA | $1,415,000,000 |
Cephalon Inc | Teva Pharmaceutical Industries | off-label or unapproved promotion of medical products | 2008 | FDA | $425,000,000 |
Otsuka American Pharmaceutical Inc. | Otsuka Pharmaceutical | off-label or unapproved promotion of medical products | 2008 | FDA | $4,000,000 |
Bristol-Myers Squibb Company | Bristol-Myers Squibb | off-label or unapproved promotion of medical products | 2007 | DOJ_CIVIL | $515,000,000 |
Medicis Pharmaceutical Corporation | Bausch Health | off-label or unapproved promotion of medical products | 2007 | DOJ_CIVIL | $9,800,000 |
Serono, S.A. | Merck KGaA (EMD) | off-label or unapproved promotion of medical products | 2005 | FDA | $704,000,000 |
Warner-Lambert | Pfizer | off-label or unapproved promotion of medical products | 2004 | FDA | $430,000,000 |
Eli Lilly and Company | Eli Lilly | off-label or unapproved promotion of medical products | 2005 | FDA | $36,000,000 |
InterMune Inc. | Roche | off-label or unapproved promotion of medical products | 2006 | FDA | $36,900,000 |
Janssen Pharmaceuticals, Inc. | Johnson & Johnson | off-label or unapproved promotion of medical products | 2013 | USAO | $410,000,000 |
Jazz Pharmaceuticals Inc. | Jazz Pharmaceuticals | off-label or unapproved promotion of medical products | 2007 | USAO | $20,000,000 |
Schering-Plough Corporation | Merck | off-label or unapproved promotion of medical products | 2006 | USAO | $435,000,000 |
Abbott Laboratories | Abbott Laboratories | off-label or unapproved promotion of medical products | 2018 | USAO | $25,000,000 |